The Sound of Evolution
Belinostat
Mechanism of action:
Belinostat is a histone deacetylase inhibitor and an epigenetic modulator. It reversibly inhibits multiple histone deacetylases (HDAC classes I, II, and IV), increasing the degree of histone acetylation. This leads to a more relaxed chromatin structure and increases the likelihood of expression of certain genes, including tumor suppressor-related genes. It can also influence the expression of genes involved in cell cycle regulation.
Reference(s):
1. Moskowitz AJ et al. (2017). Targeting histone deacetylases in T-cell lymphoma. Leuk Lymphoma.
2. Hood K et al. (2016). Belinostat for relapsed or refractory peripheral T-cell lymphoma. J Adv Pract Oncol.
3. Wang LZ et al. (2013). Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One.